TGTX
Neutral signalScored 2026-09-16 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
TG Therapeutics, Inc.
- Nom
- TG Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $8.4B
- Employés
- 399
- PDG
- Michael S. Weiss
- Site web
- https://www.tgtherapeutics.com
- Marché
- ADAGADCTCLDXCRVSGMABIPHA
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 5 000 titres (~274 800,00 $ US)
- Insiders
- Charney Laurence N
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$274,800
Avg sell (VWAP, 90d window) $54.96 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-10
- Last synced
-
2026-09-16 10:10:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-10 | Charney Laurence N | Sell · S S | 5,000 | $54.96 | ≈ $274,800 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2020-09-08 | Chris Jacobs | Sale (Partial) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-16 Drivers: fundamentals. Moteurs : fondamentaux.
TGTX presents a compelling financial turnaround story with strong improving fundamentals (liquidity 75, fundamental trend 85) and meaningful M&A catalyst momentum driven by Briumvi's commercial growth and subcutaneous…
The first sentence of the analysis written for TGTX on 2026-09-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 4.10 · operating margin 20%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 83.7% | 88.3% | 94.0% | 90.5% | 88.2% | |
| Ebit Margin | 21.8% | 15.1% | 11.0% | -7670.4% | -5119.8% | |
| Ebitda Margin | 21.8% | 15.2% | 11.2% | -7651.9% | -5112.4% | |
| Operating Profit Margin | 20.0% | 12.7% | 8.8% | -7839.0% | -5154.3% | |
| Pretax Profit Margin | 17.4% | 7.8% | 5.6% | -8036.3% | -5204.1% | |
| Continuous Operations Profit Margin | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | |
| Net Profit Margin | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | |
| Bottom Line Profit Margin | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | |
| Current Ratio | 4.102 | 6.246 | 5.919 | 3.163 | 5.062 | |
| Quick Ratio | 3.285 | 5.028 | 5.177 | 3.163 | 5.062 | |
| Solvency Ratio | 1.078 | 0.067 | 0.077 | -1.654 | -2.440 | |
| Cash Ratio | 0.515 | 1.984 | 1.730 | 1.923 | 4.571 | |
| Price To Earnings Ratio | 9.616 | 188.125 | 191.265 | -8.103 | -7.224 | |
| Price To Earnings Growth Ratio | 0.005 | 2.376 | -1.802 | 0.182 | -0.833 | |
| Forward Price To Earnings Growth Ratio | 0.005 | 2.376 | -1.802 | 0.182 | -0.833 | |
| Price To Earnings Diluted Ratio | 10.762 | 200.667 | 200.234 | -8.103 | -7.224 | |
| Price To Earnings Diluted Growth Ratio | 0.006 | 2.646 | -1.892 | 0.182 | -0.833 | |
| Price To Book Ratio | 6.639 | 19.671 | 15.106 | 27.343 | 10.593 | |
| Price To Sales Ratio | 6.981 | 13.295 | 10.376 | 575.194 | 375.577 | |
| Price To Free Cash Flow Ratio | -172.180 | -107.836 | -77.184 | -9.092 | -8.486 | |
| Price To Operating Cash Flow Ratio | -173.667 | -107.956 | -77.184 | -9.093 | -8.498 | |
| Debt To Assets Ratio | 0.245 | 0.439 | 0.336 | 0.429 | 0.208 | |
| Debt To Equity Ratio | 0.402 | 1.141 | 0.690 | 1.418 | 0.333 | |
| Debt To Capital Ratio | 0.287 | 0.533 | 0.408 | 0.586 | 0.250 | |
| Long Term Debt To Capital Ratio | 0.281 | 0.524 | 0.384 | 0.548 | 0.220 | |
| Financial Leverage Ratio | 1.641 | 2.598 | 2.053 | 3.304 | 1.601 | |
| Working Capital Turnover Ratio | 1.294 | 0.889 | 1.232 | 0.015 | 0.017 | |
| Operating Cash Flow Ratio | -0.161 | -0.447 | -0.585 | -3.311 | -4.522 | |
| Operating Cash Flow Sales Ratio | -0.040 | -0.123 | -0.134 | -63.257 | -44.197 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.009 | 1.001 | 1.000 | 1.000 | 1.001 | |
| Debt Service Coverage Ratio | 17.074 | 1.985 | 2.038 | -20.911 | -51.712 | |
| Interest Coverage Ratio | 4.614 | 1.745 | 1.636 | -21.422 | -61.151 | |
| Short Term Operating Cash Flow Coverage Ratio | -23.728 | 0.000 | 0.000 | 0.000 | -303.214 | |
| Operating Cash Flow Coverage Ratio | -0.095 | -0.160 | -0.284 | -2.121 | -3.740 | |
| Capital Expenditure Coverage Ratio | -115.757 | -900.378 | 0.000 | -12,583.571 | -737.242 | |
| Dividend Paid And Capex Coverage Ratio | -115.757 | -900.378 | 0.000 | -12,583.571 | -737.242 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 33.370 | 89.132 | 93.581 | -7.427 | -6.704 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 83.7% | ▼-4.6% | ▼-5.3% |
| Ebit Margin | 21.8% | ▲6.7% | ▲2570.2% |
| Ebitda Margin | 21.8% | ▲6.6% | ▲2565.0% |
| Operating Profit Margin | 20.0% | ▲7.3% | ▲2610.3% |
| Pretax Profit Margin | 17.4% | ▲9.7% | ▲2659.3% |
| Continuous Operations Profit Margin | 72.6% | ▲65.5% | ▲2703.6% |
| Net Profit Margin | 72.6% | ▲65.5% | ▲2703.6% |
| Bottom Line Profit Margin | 72.6% | ▲65.5% | ▲2703.6% |
| Current Ratio | 4.102 | ▼-2.143 | ▼-0.796 |
| Quick Ratio | 3.285 | ▼-1.742 | ▼-1.058 |
| Solvency Ratio | 1.077 | ▲1.011 | ▲1.652 |
| Cash Ratio | 0.515 | ▼-1.469 | ▼-1.630 |
| Price To Earnings Ratio | 9.616 | ▼-178.509 | ▼-65.120 |
| Price To Earnings Growth Ratio | 0.005 | ▼-2.371 | ▲0.019 |
| Forward Price To Earnings Growth Ratio | 0.005 | ▼-2.371 | ▲0.019 |
| Price To Earnings Diluted Ratio | 10.762 | ▼-189.905 | ▼-68.505 |
| Price To Earnings Diluted Growth Ratio | 0.006 | ▼-2.639 | ▼-0.016 |
| Price To Book Ratio | 6.639 | ▼-13.032 | ▼-9.232 |
| Price To Sales Ratio | 6.981 | ▼-6.314 | ▼-189.304 |
| Price To Free Cash Flow Ratio | -172.180 | ▼-64.344 | ▼-97.224 |
| Price To Operating Cash Flow Ratio | -173.667 | ▼-65.712 | ▼-98.388 |
| Debt To Assets Ratio | 0.245 | ▼-0.194 | ▼-0.086 |
| Debt To Equity Ratio | 0.402 | ▼-0.739 | ▼-0.395 |
| Debt To Capital Ratio | 0.287 | ▼-0.246 | ▼-0.126 |
| Long Term Debt To Capital Ratio | 0.281 | ▼-0.243 | ▼-0.111 |
| Financial Leverage Ratio | 1.641 | ▼-0.957 | ▼-0.599 |
| Working Capital Turnover Ratio | 1.294 | ▲0.405 | ▲0.604 |
| Operating Cash Flow Ratio | -0.161 | ▲0.286 | ▲1.644 |
| Operating Cash Flow Sales Ratio | -0.040 | ▲0.083 | ▲21.510 |
| Free Cash Flow Operating Cash Flow Ratio | 1.009 | ▲0.007 | ▲0.006 |
| Debt Service Coverage Ratio | 17.074 | ▲15.089 | ▲27.379 |
| Interest Coverage Ratio | 4.614 | ▲2.869 | ▲19.530 |
| Short Term Operating Cash Flow Coverage Ratio | -23.728 | ▼-23.728 | ▲41.660 |
| Operating Cash Flow Coverage Ratio | -0.095 | ▲0.065 | ▲1.185 |
| Capital Expenditure Coverage Ratio | -115.757 | ▲784.621 | ▲2751.633 |
| Dividend Paid And Capex Coverage Ratio | -115.757 | ▲784.621 | ▲2751.633 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 33.370 | ▼-55.762 | ▼-7.020 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.30B | $4.37B | $2.42B | $1.60B | $2.51B | |
| Enterprise value | $4.48B | $4.45B | $2.44B | $1.58B | $2.29B | |
| EV / Sales | 7.28x | 13.52x | 10.45x | 568.28x | 342.71x | |
| EV / Op. cash flow | -181.00x | -109.78x | -77.75x | -8.98x | -7.75x | |
| EV / Free cash flow | -179.45x | -109.66x | -77.75x | -8.98x | -7.74x | |
| EV / EBITDA | 33.37x | 89.13x | 93.58x | -7.43x | -6.70x | |
| Net debt / EBITDA | 1.35x | 1.48x | 0.68x | 0.09x | 0.64x | |
| Current ratio | 4.10x | 6.25x | 5.92x | 3.16x | 5.06x | |
| Income quality | -0.06x | -1.73x | -2.48x | 0.89x | 0.85x | |
| Graham number | $18 | $2 | $2 | — | — | |
| Graham net-net | $0 | $1 | $1 | $0 | $1 | |
| Tax burden | 416.4% | 91.4% | 97.0% | 100.0% | 100.0% | |
| Interest burden | 80.1% | 51.6% | 50.9% | 104.8% | 101.6% | |
| Working capital | $477.0M | $475.7M | $264.2M | $115.1M | $265.6M | |
| Invested capital | $483.3M | $482.8M | $273.2M | $126.7M | $277.4M | |
| Return on assets | 42.1% | 4.0% | 3.8% | -115.6% | -91.7% | |
| Operating ROA | 15.0% | 9.2% | 7.9% | -76.2% | -68.6% | |
| Return on tangible assets | 42.1% | 4.0% | 3.9% | -116.1% | -91.9% | |
| Return on equity | 69.0% | 10.5% | 7.9% | -382.0% | -146.8% | |
| Return on invested capital | 13.5% | 7.8% | 7.2% | -153.8% | -108.9% | |
| Return on capital employed | 13.6% | 8.6% | 7.5% | -155.5% | -109.7% | |
| Earnings yield | 10.4% | 0.5% | 0.5% | -14.0% | -13.9% | |
| Free cash flow yield | -0.6% | -0.9% | -1.3% | -11.0% | -11.8% | |
| Capex / Op. cash flow | -0.9% | -0.1% | 0.0% | -0.0% | -0.1% | |
| Capex / Depreciation | 362.7% | 16.1% | 0.0% | 2.7% | 81.2% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.5% | 6.0% | |
| SG&A / Sales | 37.7% | 46.9% | 52.5% | 3428.5% | 1914.9% | |
| R&D / Sales | 26.0% | 28.7% | 32.6% | 4501.0% | 3327.5% | |
| Stock comp / Sales | 10.5% | 12.9% | 16.2% | 688.9% | 916.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.2% | 0.4% | 0.2% | |
| Days sales outstanding | 181d | 143d | 80d | 0d | 76d | |
| Days payables outstanding | 390d | 0d | 0d | 0d | 0d | |
| Operating cycle | 636d | 1191d | 1108d | 0d | 76d | |
| Cash conversion cycle | 247d | 1191d | 1108d | 0d | 76d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-15 California State Teachers Retirement System Acquires 9,198,333 Shares of TG Therapeutics, Inc. $TGTX California State Teachers Retirement System lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 5,233.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 9,374,083 shares of the biopharmaceutical company''s stock after acquiring an additional 9,198,333 shares during the period. California State Teachers
- 2026-09-10 TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET
- 2026-09-03 TG Therapeutics to Participate in the Cantor Global Healthcare Conference NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
- 2026-09-02 TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue? TG Therapeutics (TGTX) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-26 TG Therapeutics: Briumvi''s Peak May Be Far Away (Rating Upgrade) TG Therapeutics, Inc.''s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 to topline Phase 3 data for Briumvi SC by year-end 2026/early 2027. TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million.
- 2026-08-23 235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG Deutsche Bank AG purchased a new stake in TG Therapeutics, Inc. (NASDAQ: TGTX) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 235,481 shares of the biopharmaceutical company''s stock, valued at approximately $12,937,000. Deutsche Bank AG owned 0.15%
- 2026-08-22 TG Therapeutics: Briumvi''s Growth Attracts Buyout Rumors Shares of TG Therapeutics rose this week after buyout rumors surfaced. TG is a prime takeover target, fueled by Briumvi''s growth and recent subcutaneous formulation de-risking. I see a potential acquisition premium of at least 45-50%, valuing TGTX at $73-76 per share, with strong standalone prospects regardless of M&A outcomes.
- 2026-08-13 Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX Bank of America Corp DE lifted its position in TG Therapeutics, Inc. (NASDAQ: TGTX) by 71.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,461,302 shares of the biopharmaceutical company''s stock after buying an additional 610,195 shares
- 2026-08-13 Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX Assenagon Asset Management S.A. decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 82.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,681 shares of the biopharmaceutical company''s stock after selling 418,373 shares during the period. Assenagon Asset
- 2026-08-11 Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) Price Target at $63.00 TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has earned an average rating of "Hold" from the nine brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average